SCHEMBL336182

SCHEMBL336182

COC(=O)c1c(O)c2cnc(SC)nc2n(C)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
KDM4E B2RXH2 4/20 0.41
EGLN1 Q9GZT9 1/20 0.39
LCK P06239 1/20 0.35
TP53 P04637 3/20 0.34
NPC1 O15118 3/20 0.34
LMNA P02545 3/20 0.34
RAB9A P51151 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NLRP3 Q96P20 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 3/20 0.34
FOS P01100 1/20 0.34
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HPGD P15428 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11168368 0.87 ALDH1A1 (0.52) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL30878848 0.83 GAA (0.44) ALDH1A1KDM4ETP53LMNASMN1; SMN2
SCHEMBL336645 0.80 EGLN1 (0.62) EGLN1
SCHEMBL10085743 0.79 EGLN1 (0.46) ALDH1A1KDM4EEGLN1TP53NPC1
SCHEMBL336458 0.78 EGLN1 (0.48) KDM4EEGLN1NPC1RAB9AMEN1
SCHEMBL11155647 0.76 ALDH1A1 (0.50) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL11152967 0.76 ALDH1A1 (0.46) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL11160518 0.75 MEN1 (0.43) ALDH1A1KDM4ENPC1LMNARAB9A
SCHEMBL2434416 0.73 ALDH1A1 (0.44) ALDH1A1KDM4EEGLN1LCKTP53
SCHEMBL29349561 0.73 KDM4E (0.42) ALDH1A1KDM4ENPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN ALDH1A1 108/4885KDM4E 248/4885EGLN1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.